Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 66.52% is 30% above its 5-year average of 51.32%, near the high end of its 5-year range (25.24%–81.01%).
As of the fiscal period ended Tuesday, June 30, 2026. 7.75% below its 12-month average of 72.11%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 66.52%.
DEBT TO ASSETS RATIO
66.52%
DEBT TO ASSETS RATIO AVG TTM
72.11%
DEBT TO ASSETS RATIO AVG 3Y
76.11%
DEBT TO ASSETS RATIO AVG 5Y
51.32%
DEBT TO ASSETS RATIO AVG 10Y
46.24%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-7.75%
CURRENT VS 3Y AVG
-12.59%
CURRENT VS 5Y AVG
+29.61%
CURRENT VS 10Y AVG
+43.87%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.10%
median of 663 covered companies
CURRENT VS SECTOR MEDIAN
+66420.19%
vs the sector median at left
iRhythm Technologies, Inc.
Market Cap
$3.49B
Debt to Assets Ratio
66.52%
TTM Avg
72.11%
3Y Avg
76.11%
5Y Avg
51.32%
Market Cap
$3.54B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.44B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.40B
Debt to Assets Ratio
0.06%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.34B
Debt to Assets Ratio
0.04%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.10B
Debt to Assets Ratio
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.10B
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iRhythm Technologies, Inc. (IRTC) | $3.49B | 66.52% | 72.11% | 76.11% | 51.32% |
| CareDx, Inc (CDNA)vs › | $3.45B | 0.04% | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.54B | 0.02% | N/A | N/A | N/A |
| Celcuity Inc. (CELC)vs › | $3.54B | 0.91% | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 0.04% | N/A | N/A | N/A |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.40B | 0.06% | N/A | N/A | N/A |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.34B | 0.04% | N/A | N/A | N/A |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.10B | 0.00% | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.10B | 0.02% | N/A | N/A | N/A |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | 0.02% | N/A | N/A | N/A |
Debt/Assets
66.5%
Debt/Equity
3.91
Current Ratio
3.87
Interest Coverage
-2.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 66.52% |
| 2026-03-31 | 72.47% |
| 2025-12-31 | 71.68% |
| 2025-09-30 | 73.65% |
| 2025-06-30 | 76.22% |
| 2025-03-31 | 79.42% |
| 2024-12-31 | 79.11% |
| 2024-09-30 | 80.84% |
| 2024-06-30 | 80.13% |
| 2024-03-31 | 81.01% |
| 2023-12-31 | 29.97% |
| 2023-09-30 | 29.96% |
| 2023-06-30 | 30.10% |
| 2023-03-31 | 31.06% |
| 2022-12-31 | 29.24% |
| 2022-09-30 | 29.37% |
| 2022-06-30 | 30.11% |
| 2022-03-31 | 30.97% |
| 2021-12-31 | 25.43% |
| 2021-09-30 | 25.31% |
| 2021-06-30 | 25.24% |
| 2021-03-31 | 25.97% |
| 2020-12-31 | 23.93% |
| 2020-09-30 | 26.93% |
| 2020-06-30 | 48.89% |
| 2020-03-31 | 48.11% |
| 2019-12-31 | 42.00% |
| 2019-09-30 | 41.85% |
| 2019-06-30 | 62.91% |
| 2019-03-31 | 37.52% |
| 2018-12-31 | 29.15% |
| 2018-09-30 | 27.36% |
| 2018-06-30 | 26.94% |
| 2018-03-31 | 27.82% |
| 2017-12-31 | 25.52% |
| 2017-09-30 | 25.09% |
| 2017-06-30 | 24.62% |
| 2017-03-31 | 24.59% |
| 2016-12-31 | 23.33% |
| 2016-09-30 | 116.13% |
| 2016-06-30 | 109.22% |
| 2015-12-31 | 80.67% |
| 2015-09-30 | 34.15% |
| 2014-12-31 | 33.79% |
